GCT1184-04/GOG3134 A Randomized, Open-label, Phase 3 study of Rinatabart Sesutecan (Rina-S) plus Standard of Care versus Standard of Care as Maintenance Treatment after 2L Platinum-based Doublet Chemotherapy in Participants with Recurrent Platinum-sensitive Ovarian Cancer (PSOC)



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Methodist Estabrook Cancer Center, Omaha, NE

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*